Many investors and analysts expect that the changes to the corporate tax code will lead to increased merger and acquisition activity in 2018. Source: BioSpace

The U.S. Food and Drug Administration is set to rule on Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase (SYK) inhibitor, for adult patients with chronic or persistent immune thrombocytopenia…

The Suzhou-based cancer-drug maker has been discussing a valuation of more than $1 billion. Source: BioSpace

Here are three biopharma stocks worth keeping an eye on. Source: BioSpace

The purpose of the subsidiary is to support the Company’s Japanese clinical and radiopharmaceutical manufacturing activities and to establish a commercial footprint in the Japan, an important market for Telix’s…

Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace

According to a SEC filing, the cost of the facility will be paid in part by the State of New York. Source: BioSpace

The move is part of the company’s strategy as it shifts from a consumer products company into a health tech company. Source: BioSpace

Mr Paulson will assume oversight of all areas supporting the North American business effective from February 5th. Source: BioSpace

In the world of Alzheimer's disease research, the names of some companies attempting to find an efficacious therapy stand out. Source: BioSpace